New combo therapy shows promise for Tough-to-Treat breast cancer
NCT ID NCT05253911
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study followed 49 adults with advanced HER2-positive breast cancer who had already tried at least two other treatments. They received a combination of tucatinib, trastuzumab, and capecitabine in a real-world setting. The goal was to see how the treatment affected their quality of life and how long it kept the cancer from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie
Vienna, 1090, Austria
-
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
Essen, North Rhine-Westphalia, D-45112, Germany
Conditions
Explore the condition pages connected to this study.